Clinical Trial Update: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous leuprolide acetate for ovarian suppression in breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eligard (leuprolide acetate)

Snippet

Sponsor: Tolmar Inc. | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING